Edgestream Partners L.P. purchased a new stake in Zoetis Inc. (NYSE:ZTS – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 18,949 shares of the company’s stock, valued at approximately $1,323,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis during the 1st quarter worth about $28,000. Wellington Grp LLC raised its position in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after purchasing an additional 267 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis in the 2nd quarter worth about $25,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after buying an additional 296 shares during the period. Finally, Dakota Community Bank & Trust NA boosted its position in shares of Zoetis by 112.4% during the first quarter. Dakota Community Bank & Trust NA now owns 393 shares of the company’s stock valued at $46,000 after buying an additional 208 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Zoetis Stock Down 2.1%
Shares of NYSE:ZTS opened at $79.09 on Friday. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49. The stock has a market cap of $32.14 billion, a P/E ratio of 13.45, a price-to-earnings-growth ratio of 1.14 and a beta of 0.67. The business’s 50 day moving average is $77.16 and its 200 day moving average is $90.55. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51.
Zoetis Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is 36.05%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on ZTS shares. TD Cowen reduced their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. BNP Paribas Exane cut their price objective on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. BTIG Research dropped coverage on Zoetis in a research note on Friday, October 30th. They issued a “buy” rating and a $200.00 target price on the stock. Piper Sandler decreased their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $101.25.
Read Our Latest Analysis on ZTS
Recent Zoetis Headlines
Here are a few of the latest headlines about ZTS:
- Positive Sentiment: The USDA licensed Zoetis’s Poulvac® Procerta® HVT-ND-ILT, a vaccine for chickens targeting three diseases. The approval expands the company’s poultry-health portfolio and could create a commercial opportunity, though the headlines provide no sales or earnings estimates. Article: Zoetis Receives USDA License for Poulvac Procerta HVT-ND-ILT Vaccine for Chickens
- Positive Sentiment: Recent coverage also highlighted news about a dog-allergy treatment and described Zoetis shares as potentially inexpensive. The headline does not provide enough detail to assess the treatment’s likely financial impact. Article: Zoetis Stock Still Looks Cheap Following Fresh Dog Allergy Treatment News
- Neutral Sentiment: Brokerages’ consensus target price is reported at $101.25, while Barclays maintained a Hold rating—signals of potential upside in analyst estimates but also a cautious view from at least one firm. Article: Zoetis Stock Has Consensus Target Price of $101.25 According to Brokerages Article: Barclays Remains a Hold on Zoetis
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
